The United States and many other countries around the world are still debating the rollout of an additional dose, or “booster” shot, of the Covid-19 vaccine. On Friday the US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee will meet to discuss Pfizer’s application to administer a third dose of its Covid-19 vaccine to people ages 16 and older. Though a recent Lancet article advises caution in administering boosters before we have the evidence to fully support that the immunological benefits outweigh any risks, to me, the science seems clear: for those in the US who received mRNA vaccines, a third dose is the minimum we should pursue for Covid-19 protection, and people should prepare themselves for the possibility that they will need additional doses or annual shots in the months and years to come. For those who received the Johnson & Johnson vaccine, there is not enough data so far to say with certainty whether a booster is advisable. Read the full article on CNN by clicking here.